<div id="readability-page-1"><p>Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) reached a new 52-week high on Friday . The stock traded as high as $40.71 and last traded at $39.93, with a volume of 5771 shares. The stock had previously closed at $40.22.</p><h2>Wall Street Analyst Weigh In</h2><ul><li>Growth Picks: 3 Low-Cost Stocks That Could Double in Value</li></ul><p>A number of equities analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of Immunocore from $34.00 to $36.00 and gave the company an &#34;equal weight&#34; rating in a research report on Monday, November 10th. Guggenheim started coverage on shares of Immunocore in a research note on Thursday, September 18th. They issued a &#34;neutral&#34; rating for the company. HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, October 22nd. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Immunocore in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Immunocore from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, four have assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat, Immunocore  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $61.00.</p><p><b>Read Our Latest Report on Immunocore</b></p><h2>Immunocore Trading Down 3.2%</h2><ul><li>3 Fast-Growing Stocks Analysts See Doubling in Price</li></ul><p>The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -68.16 and a beta of 0.77. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The firm's 50 day moving average is $35.06 and its 200 day moving average is $34.23. </p><p>Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.32. The company had revenue of $103.69 million for the quarter, compared to analysts' expectations of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The firm's revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 earnings per share.  Equities analysts forecast that  Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year. </p><h2>Insider Buying and Selling at Immunocore</h2><ul><li>Institutions are Buying These 3 Stocks and Analysts Agree</li></ul><p>In related news, insider David M. Berman sold 22,532 shares of Immunocore stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.40% of the stock is owned by company insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of  Immunocore by 51.6% in the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company's stock valued at $33,000 after acquiring an additional 311 shares in the last quarter.  DNB Asset Management AS lifted its holdings in shares of  Immunocore by 6.4% in the third quarter. DNB Asset Management AS now owns 8,116 shares of the company's stock valued at $295,000 after purchasing an additional 488 shares in the last quarter.  Virtus Investment Advisers LLC lifted its holdings in shares of  Immunocore by 5.3% in the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company's stock valued at $391,000 after purchasing an additional 625 shares in the last quarter.  Orion Porfolio Solutions LLC boosted its position in shares of  Immunocore by 4.5% in the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company's stock worth $752,000 after buying an additional 1,031 shares during the period.  Finally, Assetmark Inc. grew its holdings in shares of  Immunocore by 3.7% during the second quarter. Assetmark Inc. now owns 34,958 shares of the company's stock valued at $1,097,000 after buying an additional 1,248 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors. </p><h2>Immunocore Company Profile</h2> (Get Free Report)<p>Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.</p><h2>See Also</h2><ul><li>Five stocks we like better than Immunocore</li><li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li><li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li><li>What is a SEC Filing?</li><li>Marvell's Rally Extends: Data Centers and AMZN Chips Boost Shares</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Immunocore Right Now?</h2><p>Before you consider Immunocore, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.</p><p>While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IMCR

<p>Immunocore Holdings PLC (NASDAQ:IMCR) reached a new 52-week high, trading as high as $40.71. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and an average target price of $61.00. The company reported better-than-expected earnings, with revenue up 29.2% year-over-year. Insider and institutional activities show significant stock transactions. Immunocore develops immunotherapies for cancer and other diseases.</p>

Immunocore (NASDAQ:IMCR) Reaches New 1-Year High - Here's What Happened